Company intelligence / Profile preview

BONiFIN

Bad Nauheim, Hesse, Germany

Ownership: Private
Development stage: Other

Overview

BONiFIN is a German biotechnology company focused on developing innovative therapies for pulmonary arterial hypertension (PAH). The company's lead program centers on a first-in-class small molecule activator of the Bone Morphogenetic Protein Receptor Type 2 (BMPR2) signaling pathway. By targeting the underlying genetic and molecular causes of PAH, BONiFIN aims to provide disease-modifying treatments that go beyond current vasodilatory therapies. The company is a spin-off from the Max Planck Institute for Heart and Lung Research and the Justus Liebig University Giessen.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Max Planck Institute for Heart and Lung ResearchJustus Liebig University Giessen

Beyond the preview

Go deeper on BONiFIN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BONiFIN.

Explore the full profile